Key result
18F-FDG PET/CT has emerged as a promising technique for the early diagnosis of anthracycline-related cardiotoxicity by detecting increased myocardial glucose uptake before contractile dysfunction occurs.
Why the study?
Anthracyclines frequently cause cardiotoxicity, and 18F-FDG PET/CT has emerged as a promising technique for early diagnosis that warrants synthesis of available evidence.
Does 18F-FDG PET/CT improve the early diagnosis of cardiotoxicity in patients undergoing anthracycline chemotherapy?
Does 18F-FDG PET/CT improve the early diagnosis of cardiotoxicity in patients undergoing anthracycline chemotherapy?
18F-FDG PET/CT may serve as a promising early biomarker for anthracycline-induced cardiotoxicity by detecting metabolic changes that precede structural and functional decline.
Despite advances in chemotherapy, the drugs used in cancer treatment remain rather harmful to the cardiovascular system, causing structural and functional cardiotoxic changes. Positron-emission tomography associated with computed tomography (PET/CT) has emerged like a promising technique in the early diagnosis of these adverse drug effects as the myocardial tissue uptake of fluorodeoxyglucose labeled with fluorine-18 ( 18 F-FDG), a glucose analog, is increased after their use. Among these drugs, anthracyclines are the most frequently associated with cardiotoxicity because they promote heart damage through DNA breaks, and induction of an oxidative, proinflammatory, and toxic environment. This review aimed to present the scientific evidence available so far regarding the use of 18 F-FDG PET/CT as an early biomarker of anthracycline-related cardiotoxicity. Thus, it discusses the physiological basis for its uptake, hypotheses to justify its increase in the myocardium affected by anthracyclines, importance of 18 F-FDG PET/CT findings for cardio-oncology, and primary challenges of incorporating this technique in standard clinical oncology practice.
No takes yet. Share an insight, caveat, or question.
Becker et al. (2023) conducted a review in Anthracycline cardiotoxicity. 18F-FDG PET/CT was evaluated. 18F-FDG PET/CT has emerged as a promising technique for the early diagnosis of anthracycline-related cardiotoxicity by detecting increased myocardial glucose uptake before contractile dysfunction occurs.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: